Our Associates, Clients and Partners are at the heart of everything we do. We remain committed to providing critical medical device development services while also protecting our communities throughout the COVID-19 Pandemic.
We invite you to access any of the below complimentary resources to learn more about strategies and best practices that can assist Sponsors to proactively address COVID-19 throughout their medical device development and commercialization programs. Additionally, NAMSA’s statement on COVID-19 and its impact to business operations can be found here.
COMING SOON! August 19, 2020 (11 AM – 12 PM ET):
Webinar: Considerations for Clinical Study Start-Up in a Virtual Environment
Register Here!
White Paper: Navigating Clinical Trials in the Era of COVID-19: An Assessment of Short-Term and Long-Term Strategies
Release Date: August 4
Webinar: How to Manage Clinical Study Data During the COVID-19 Pandemic
Release Date: May 13
Webinar: The COVID-19 Pandemic – Proper Clinical Study Management & Protecting Data Validity
Blog Post: European Commission Mandate for EU Parliament Negotiations on MDR Delay: Clarification Regarding Article 120 Section 3
Release Date: April 9
Podcast: COVID-19: Biocompatibility of Ventilators and Respiratory Devices
Release Date: April 7
Blog Post: EU Response to COVID-19 Pandemic: Proposal to Delay Date of MDR Application to May 2021 for Certain Provisions
Release Date: April 3
Blog Post: Diagnostic Developers Look to EUA Submission to Combat COVID-19
NAMSA, as the industry leader in IVD regulatory knowledge and product development, is proud to have partnered with several domestic and overseas IVD Sponsors for Emergency Use Authorization (EUA) assay submissions to combat COVID-19. IVD Sponsors seeking expedited EUA development of Serology and Molecular assays, are encouraged to reach out to us to learn more. Let us help you in delivering much-needed COVID-19 diagnostics to advance patient healthcare around the globe. Contact us here